The Impact of Pathogenic BRCA1/2 Tumor Mutation Status on Advanced Stage-High Grade Serous Epithelial Ovarian Cancer Survival Outcome

The Impact of Pathogenic BRCA1/2 Tumor Mutation Status on Advanced Stage-High Grade Serous Epithelial Ovarian Cancer Survival Outcome | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article The Impact of Pathogenic BRCA1/2 Tumor Mutation Status on Advanced Stage-High Grade Serous Epithelial Ovarian Cancer Survival Outcome Sutrisno Sutrisno, Sigit Purbadi, Hartono Tjahjadi, Retno Asti Werdhani, and 8 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1745126/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Objective: To evaluate the impact of pathogenic BRCA1/2 tumor mutation on advanced stage-high grade serous epithelial ovarian cancer (HGSOC) survival outcome. Methods: A total of 68 from 144 patients were diagnosed with FIGO 2014 stage IIB-IV HGSOC between January 1st 2015, until March 31st 2021, at Dr. Cipto Mangunkusumo National Central Referral Hospital, Persahabatan Central Referral Hospital, and MRCCC Central Referral Hospital Siloam Jakarta, underwent NGS tumor BRCA1/2 gene testing and were included in this cohort historical study. We compared patient’s overall survival outcomes to pathogenic BRCA1/2 tumor mutational status. The patient’s clinicopathological characteristic factors that might affect patient’s survival outcomes were also investigated. Results: In the group with pathogenic BRCA1/2 tumor mutation, the likelihood of dying was 86% ​​lower (adjusted RR 0.149; 95%CI 0.046-0.475; p-value=0.001), and the median survival was better (median 46 months; 95%CI 34.009-57.991; p value=0.001) than the group without pathogenic BRCA1/2 tumor mutations (median 23 months; 95%CI 15.657-30.343; p value=0.001). The multivariate analyses identified pathogenic BRCA1/2 tumor mutation as an independent favorable prognostic factor for survival outcome (adjusted RR 0.149; 95%CI 0.046-0.475; p-value=0.001). Conclusions: In advanced stage-HGSOC patients, the pathogenic BRCA1/2 tumor mutations group have a better prognosis with longer survival outcomes than those without pathogenic BRCA1/2 tumor mutations. Ovarian Neoplasms High-Grade Serous Epithelial Ovarian Carcinoma BRCA1/2 Clinical Outcome Survival Outcome Full Text Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1745126","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":112820411,"identity":"24b7ef09-db40-4303-bffb-31e72d42c1fb","order_by":0,"name":"Sutrisno Sutrisno","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA80lEQVRIiWNgGAWjYLCCBCBmY28+/OADmEFQPTNECz/PsTTDGSAtzMRoAQHJGT4G0jxIAjiB/Iz8Yx8e/LkjZ3CDLcHY5tc2eT5mBsYPH3NwazG4kcw8I7HtmbHB7eYDj3P7bhu2MTMwS87chkeLRDIzQ2LD4cQNd44lGOf23GYEamFj5sWjRX4GUEvCH6CWGzkG0pY9t+0JamG4AdLCdjhx5gygFoYftxMJajE489iYIbHtsDE4kHsbbie3MTM24/WLfHviY8Yffw7LgaPyx5/btvPbmw9++IjPYSiAsQ1MNhCrHgT+kKJ4FIyCUTAKRgoAACsTU4xeY/8PAAAAAElFTkSuQmCC","orcid":"","institution":"University of Indonesia","correspondingAuthor":true,"prefix":"","firstName":"Sutrisno","middleName":"","lastName":"Sutrisno","suffix":""},{"id":112820412,"identity":"5cfcf3cb-4546-4556-a1ad-577a58fa49cb","order_by":1,"name":"Sigit Purbadi","email":"","orcid":"","institution":"University of Indonesia","correspondingAuthor":false,"prefix":"","firstName":"Sigit","middleName":"","lastName":"Purbadi","suffix":""},{"id":112820413,"identity":"5b7fe89f-d738-4f86-923d-765ae0788242","order_by":2,"name":"Hartono Tjahjadi","email":"","orcid":"","institution":"University of Indonesia","correspondingAuthor":false,"prefix":"","firstName":"Hartono","middleName":"","lastName":"Tjahjadi","suffix":""},{"id":112820414,"identity":"65d0469b-5c47-49c7-9f5c-79a4d877b1a4","order_by":3,"name":"Retno Asti Werdhani","email":"","orcid":"","institution":"University of Indonesia","correspondingAuthor":false,"prefix":"","firstName":"Retno","middleName":"Asti","lastName":"Werdhani","suffix":""},{"id":112820415,"identity":"ec644222-cd11-4026-8de4-6fe6142b16ce","order_by":4,"name":"Oni Khonsa","email":"","orcid":"","institution":"University of Indonesia","correspondingAuthor":false,"prefix":"","firstName":"Oni","middleName":"","lastName":"Khonsa","suffix":""},{"id":112820416,"identity":"825d0ee4-626b-46ea-8ce8-14a8f5cd0a96","order_by":5,"name":"Ruth Emalian Sembiring","email":"","orcid":"","institution":"University of Indonesia","correspondingAuthor":false,"prefix":"","firstName":"Ruth","middleName":"Emalian","lastName":"Sembiring","suffix":""},{"id":112820417,"identity":"52b47c24-bca8-456c-88b2-f197d1b42fbd","order_by":6,"name":"Iwan Kurnia Effendi","email":"","orcid":"","institution":"MRCCC Central Referral Hospital Siloam Jakarta","correspondingAuthor":false,"prefix":"","firstName":"Iwan","middleName":"Kurnia","lastName":"Effendi","suffix":""},{"id":112820418,"identity":"c4e7bcdc-3077-4547-9387-25a919495851","order_by":7,"name":"Fajar Lamhot Gultom","email":"","orcid":"","institution":"MRCCC Central Referral Hospital Siloam Jakarta","correspondingAuthor":false,"prefix":"","firstName":"Fajar","middleName":"Lamhot","lastName":"Gultom","suffix":""},{"id":112820419,"identity":"769c9ccf-7f96-45bf-91fd-d70ec6fd8ae2","order_by":8,"name":"Stella Marleen","email":"","orcid":"","institution":"MRCCC Central Referral Hospital Siloam Jakarta","correspondingAuthor":false,"prefix":"","firstName":"Stella","middleName":"","lastName":"Marleen","suffix":""},{"id":112820420,"identity":"cd72d4af-77b8-46f3-97de-991b6f4cd7b0","order_by":9,"name":"Sony Sugiharto","email":"","orcid":"","institution":"MRCCC Central Referral Hospital Siloam Jakarta","correspondingAuthor":false,"prefix":"","firstName":"Sony","middleName":"","lastName":"Sugiharto","suffix":""},{"id":112820421,"identity":"1deee612-bcfb-41d5-aaab-17867a8b6409","order_by":10,"name":"Ardiana Hendrasti","email":"","orcid":"","institution":"MRCCC Central Referral Hospital Siloam Jakarta","correspondingAuthor":false,"prefix":"","firstName":"Ardiana","middleName":"","lastName":"Hendrasti","suffix":""},{"id":112820422,"identity":"a07d89dc-d26d-4c88-b761-bdcb71e17c4b","order_by":11,"name":"Nastiti Maharani","email":"","orcid":"","institution":"Jenderal Soedirman University","correspondingAuthor":false,"prefix":"","firstName":"Nastiti","middleName":"","lastName":"Maharani","suffix":""}],"badges":[],"createdAt":"2022-06-10 10:59:15","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1745126/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1745126/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":22602838,"identity":"e8d30985-bb3e-4234-a545-1cda3f318c42","added_by":"auto","created_at":"2022-06-13 21:48:12","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":754041,"visible":true,"origin":"","legend":"","description":"","filename":"editspringerMANUSCRIPTBRCAMUTATIONSUTRISNOIFINAL2022.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1745126/v1_covered.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"The Impact of Pathogenic BRCA1/2 Tumor Mutation Status on Advanced Stage-High Grade Serous Epithelial Ovarian Cancer Survival Outcome","fulltext":[{"header":"Full Text","content":"This preprint is available for \u003ca href='/article/rs-1745126/latest.pdf' target='_blank'\u003edownload as a PDF\u003c/a\u003e."}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Ovarian Neoplasms, High-Grade Serous Epithelial Ovarian Carcinoma, BRCA1/2, Clinical Outcome, Survival Outcome","lastPublishedDoi":"10.21203/rs.3.rs-1745126/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1745126/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eObjective: To evaluate the impact of pathogenic BRCA1/2 tumor mutation on advanced stage-high grade serous epithelial ovarian cancer (HGSOC) survival outcome. \u003c/p\u003e\u003cp\u003eMethods: A total of 68 from 144 patients were diagnosed with FIGO 2014 stage IIB-IV HGSOC between January 1st 2015, until March 31st 2021, at Dr. Cipto Mangunkusumo National Central Referral Hospital, Persahabatan Central Referral Hospital, and MRCCC Central Referral Hospital Siloam Jakarta, underwent NGS tumor BRCA1/2 gene testing and were included in this cohort historical study. We compared patient’s overall survival outcomes to pathogenic BRCA1/2 tumor mutational status. The patient’s clinicopathological characteristic factors that might affect patient’s survival outcomes were also investigated. \u003c/p\u003e\u003cp\u003eResults: In the group with pathogenic BRCA1/2 tumor mutation, the likelihood of dying was 86% ​​lower (adjusted RR 0.149; 95%CI 0.046-0.475; p-value=0.001), and the median survival was better (median 46 months; 95%CI 34.009-57.991; p value=0.001) than the group without pathogenic BRCA1/2 tumor mutations (median 23 months; 95%CI 15.657-30.343; p value=0.001). The multivariate analyses identified pathogenic BRCA1/2 tumor mutation as an independent favorable prognostic factor for survival outcome (adjusted RR 0.149; 95%CI 0.046-0.475; p-value=0.001).\u003c/p\u003e\u003cp\u003eConclusions: In advanced stage-HGSOC patients, the pathogenic BRCA1/2 tumor mutations group have a better prognosis with longer survival outcomes than those without pathogenic BRCA1/2 tumor mutations.\u003c/p\u003e","manuscriptTitle":"The Impact of Pathogenic BRCA1/2 Tumor Mutation Status on Advanced Stage-High Grade Serous Epithelial Ovarian Cancer Survival Outcome","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-06-13 21:48:05","doi":"10.21203/rs.3.rs-1745126/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"ceb0a2a6-ad8f-40e1-a2d3-b8dbf278efe0","owner":[],"postedDate":"June 13th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2022-06-13T21:48:07+00:00","versionOfRecord":[],"versionCreatedAt":"2022-06-13 21:48:05","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-1745126","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1745126","identity":"rs-1745126","version":["v1"]},"buildId":"_2-kVJe1T_tPrBINL-cwx","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}